"A slow start for self-amplifying mRNA vaccines" was originally created and published by Pharmaceutical Technology, a ...
BTIG initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $41 price target Arcturus is a commercial-stage biotechnology ...
a self-amplifying mRNA (sa-mRNA) vaccine candidate, also known as LUNAR-H5N1, for active immunization to prevent pandemic influenza disease caused by H5N1 virus. The primary objective of this ...
Arcturus’ lead clinical stage product candidates include a first-in-class, self-amplifying mRNA vaccine for COVID-19 and an mRNA replacement therapy for ornithine transcarbamylase (OTC ...
A significant breakthrough in RNA therapeutics, this self-amplifying technology overcomes ... efficacy at 100X lower doses than conventional mRNA. "This advancement solves a longstanding challenge ...
In contrast, saRNA delivered into a cell first self-amplifies, resulting in very high mRNA copy numbers, thereby achieving superior gene expression and an amplified protein response with a much ...
Japan is the first country to put a self-amplifying mRNA vaccine into practical use. The health ministry’s expert committee that approved the replicon vaccine has said, “It is desirable to ...
Five types of vaccines are available, and the list includes, for the first time, a new type of mRNA vaccine that uses a self-amplifying RNA (saRNA) technology called “replicon," manufactured by ...